ADVERTISEMENT

FDA approves CAR T-cell therapy for R/R multiple myeloma

Pavankumar Kamat   |   Clinical Summary   |   07 March 2022
ADVERTISEMENT

Takeaway

  • The US Food and Drug Administration (FDA) has approved the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with refractory/relapsed multiple myeloma (R/R MM) who have previously received 4 therapies.

Why this matters

  • Cilta-cel is a novel CAR T-cell therapy targeting the...

          

Topic Challenges

left
right